Amneal Pharmaceuticals (AMRX) Competitors

$12.23 +0.42 (+3.56%)

Closing price 05/20/2026 04:00 PM Eastern

Extended Trading

$12.18 -0.05 (-0.45%)

As of 09:09 AM Eastern

AMRX vs. ASND, SMMT, BBIO, RGC, and AXSM

Should you buy Amneal Pharmaceuticals stock or one of its competitors? MarketBeat compares Amneal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amneal Pharmaceuticals include Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), Regencell Bioscience (RGC), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Amneal Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.41, suggesting that its share price is 59% less volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.29	$72.06M	$0.38	32.18
Ascendis Pharma A/S	$814.57M	18.48	-$258M	$8.67	27.84

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 5 mentions for Ascendis Pharma A/S. Amneal Pharmaceuticals' average media sentiment score of 1.04 beat Ascendis Pharma A/S's score of 0.67 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Amneal Pharmaceuticals' net margin of 4.01%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

Amneal Pharmaceuticals currently has a consensus price target of $15.17, suggesting a potential upside of 24.01%. Ascendis Pharma A/S has a consensus price target of $295.39, suggesting a potential upside of 22.40%. Given Amneal Pharmaceuticals' higher possible upside, equities analysts plainly believe Amneal Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, analyst recommendations, dividends, earnings, risk, valuation and institutional ownership.

Summit Therapeutics presently has a consensus target price of $27.58, suggesting a potential upside of 54.18%. Amneal Pharmaceuticals has a consensus target price of $15.17, suggesting a potential upside of 24.01%. Given Summit Therapeutics' higher probable upside, research analysts clearly believe Summit Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.50
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Amneal Pharmaceuticals had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 3 mentions for Summit Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 1.04 beat Summit Therapeutics' score of 0.32 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 4.01% compared to Summit Therapeutics' net margin of 0.00%. Summit Therapeutics' return on equity of -291.24% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summit Therapeutics has a beta of -1.25, indicating that its share price is 225% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Amneal Pharmaceuticals	$3.02B	1.29	$72.06M	$0.38	32.18

Summary

Amneal Pharmaceuticals beats Summit Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Amneal Pharmaceuticals (NASDAQ:AMRX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, BridgeBio Pharma had 6 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 12 mentions for BridgeBio Pharma and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.04 beat BridgeBio Pharma's score of 0.65 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 4.01% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.29	$72.06M	$0.38	32.18
BridgeBio Pharma	$502.08M	26.61	-$724.93M	-$3.74	N/A

Amneal Pharmaceuticals has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Amneal Pharmaceuticals currently has a consensus target price of $15.17, indicating a potential upside of 24.01%. BridgeBio Pharma has a consensus target price of $88.90, indicating a potential upside of 30.32%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
BridgeBio Pharma	1 Sell rating(s)	1 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.88

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Regencell Bioscience's net margin of 0.00%. Regencell Bioscience's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

0.1% of Regencell Bioscience shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 2.0% of Regencell Bioscience shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher revenue and earnings than Regencell Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.29	$72.06M	$0.38	32.18

Regencell Bioscience has a beta of 1.88, suggesting that its share price is 88% more volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

Amneal Pharmaceuticals has a consensus price target of $15.17, indicating a potential upside of 24.01%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Regencell Bioscience had 12 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 18 mentions for Regencell Bioscience and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 1.04 beat Regencell Bioscience's score of 0.00 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Amneal Pharmaceuticals beats Regencell Bioscience on 10 of the 13 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment.

Amneal Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.59	-$183.17M	-$3.73	N/A
Amneal Pharmaceuticals	$3.02B	1.29	$72.06M	$0.38	32.18

Axsome Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market.

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Axsome Therapeutics currently has a consensus price target of $251.26, suggesting a potential upside of 8.95%. Amneal Pharmaceuticals has a consensus price target of $15.17, suggesting a potential upside of 24.01%. Given Amneal Pharmaceuticals' higher possible upside, analysts plainly believe Amneal Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88

In the previous week, Amneal Pharmaceuticals had 4 more articles in the media than Axsome Therapeutics. MarketBeat recorded 6 mentions for Amneal Pharmaceuticals and 2 mentions for Axsome Therapeutics. Amneal Pharmaceuticals' average media sentiment score of 1.04 beat Axsome Therapeutics' score of 0.02 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Amneal Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 4.01% compared to Axsome Therapeutics' net margin of -26.59%. Axsome Therapeutics' return on equity of -267.16% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Summary

Amneal Pharmaceuticals beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.77B	$2.99B	$6.30B	$12.11B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	32.19	17.63	20.82	25.31
Price / Sales	1.29	248.41	518.38	71.03
Price / Cash	7.56	56.99	43.18	55.00
Price / Book	-87.36	4.53	9.87	6.94
Net Income	$72.06M	$74.99M	$3.55B	$335.25M
7 Day Performance	N/A	-3.81%	-0.83%	-1.39%
1 Month Performance	-6.07%	-5.39%	-1.18%	0.09%
1 Year Performance	68.23%	35.50%	33.67%	32.51%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	4.3914 of 5 stars	$12.23 +3.6%	$15.17 +24.0%	+64.8%	$3.77B	$3.02B	32.19	8,500	Positive News Analyst Forecast
ASND Ascendis Pharma A/S	3.8597 of 5 stars	$243.01 +1.8%	$291.50 +20.0%	+49.4%	$15.16B	$814.57M	28.03	1,189	Positive News Analyst Upgrade
SMMT Summit Therapeutics	2.7775 of 5 stars	$18.80 +0.7%	$27.58 +46.8%	-26.7%	$14.59B	N/A	N/A	110	Positive News Analyst Downgrade Options Volume
BBIO BridgeBio Pharma	3.6721 of 5 stars	$64.98 +0.5%	$88.19 +35.7%	+102.4%	$12.76B	$502.08M	N/A	400	Analyst Forecast Insider Trade
RGC Regencell Bioscience	0.422 of 5 stars	$25.80 -5.6%	N/A	N/A	$12.76B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. ASND, SMMT, BBIO, RGC, and AXSM

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Amneal Pharmaceuticals compare to Summit Therapeutics?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Amneal Pharmaceuticals compare to Regencell Bioscience?

Summary

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. ASND, SMMT, BBIO, RGC, and AXSM

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Which has more risk and volatility, AMRX or ASND?

Which has preferable earnings and valuation, AMRX or ASND?

Does the media refer more to AMRX or ASND?

Is AMRX or ASND more profitable?

Do analysts prefer AMRX or ASND?

Do insiders & institutionals hold more shares of AMRX or ASND?

Summary

How does Amneal Pharmaceuticals compare to Summit Therapeutics?

Do analysts recommend SMMT or AMRX?

Does the media prefer SMMT or AMRX?

Is SMMT or AMRX more profitable?

Do insiders and institutionals hold more shares of SMMT or AMRX?

Which has more volatility & risk, SMMT or AMRX?

Which has better valuation & earnings, SMMT or AMRX?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Does the media refer more to AMRX or BBIO?

Is AMRX or BBIO more profitable?

Which has preferable valuation and earnings, AMRX or BBIO?

Which has more volatility and risk, AMRX or BBIO?

Do analysts recommend AMRX or BBIO?

Do institutionals & insiders believe in AMRX or BBIO?

Summary

How does Amneal Pharmaceuticals compare to Regencell Bioscience?

Is RGC or AMRX more profitable?

Do insiders & institutionals believe in RGC or AMRX?

Which has better valuation and earnings, RGC or AMRX?

Which has more risk and volatility, RGC or AMRX?

Do analysts rate RGC or AMRX?

Does the media prefer RGC or AMRX?

Summary

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Which has higher earnings & valuation, AXSM or AMRX?

Which has more risk and volatility, AXSM or AMRX?

Do institutionals & insiders have more ownership in AXSM or AMRX?

Do analysts prefer AXSM or AMRX?

Does the media refer more to AXSM or AMRX?

Is AXSM or AMRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools